argenx SE (argenx SE) Total Long-Term Liabilities : $22 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. argenx SE's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was $22 Mil.

argenx SE Total Long-Term Liabilities Historical Data

The historical data trend for argenx SE's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Total Long-Term Liabilities Chart

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

250.11

276.86

14.81

18.29

21.96

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Long-Term Liabilities	Get a 7-Day Free Trial															18.29	-	17.95	-	21.96

argenx SE Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

argenx SE Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of argenx SE's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.